Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study

Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, Sieder C, Melzer N, Sticherling M (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 145-145

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Novartis AG CH Switzerland (CH) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Dermatologikum Hamburg DE Germany (DE)

How to cite

APA:

Mrowietz, U., Augustin, M., Thaci, D., Reich, K., Kneidl, J., Hentschke, C.,... Sticherling, M. (2017). Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study. (pp. 145-145).

MLA:

Mrowietz, U., et al. "Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study." 2017. 145-145.

BibTeX: Download